Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth

• Main Authors: Sorah Yoon (Author), Kai-Wen Huang (Author), Vikash Reebye (Author), Duncan Spalding (Author), Teresa M. Przytycka (Author), Yijie Wang (Author), Piotr Swiderski (Author), Lin Li (Author), Brian Armstrong (Author), Isabella Reccia (Author), Dimitris Zacharoulis (Author), Konstantinos Dimas (Author), Tomokazu Kusano (Author), John Shively (Author), Nagy Habib (Author), John J. Rossi (Author)
• Format: Book
• Published: Elsevier, 2017-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aptamer-drug conjugates (ApDCs) have the potential to improve the therapeutic index of traditional chemotherapeutic agents due to their ability to deliver cytotoxic drugs specifically to cancer cells while sparing normal cells. This study reports on the conjugation of cytotoxic drugs to an aptamer p...